

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

Support for the amendment can be found in paragraph 148 and the portion of the table shown on page 46.

The rejection of claims 63-76 and 89-92 under 35 U.S.C. §101 as being drawn to non-statutory subject matter is respectfully traversed in view of the above amendments. The claims provide a transformation of matter into a different state or thing.

The rejection of claims 63-76 and 89-92 under 35 U.S.C. §112(first paragraph) for lack of enablement is respectfully traversed in view of the above amendments.

The rejection of claims 63-76 and 89-92 under 35 U.S.C. §112(second paragraph) for indefiniteness is respectfully traversed in view of the above amendments.

The rejection of claims 63-76 under 35 U.S.C. §102(b) as anticipated by WO/0022166 is respectfully traversed.

The WO/0022166 application does not, however, disclose or suggest methods which include genotyping a single nucleotide polymorphism in baySNP 8242, baySNP 900066 and baySNP 900073, as claimed in the present application.

In view of the foregoing, applicants submit that the above identified patent application is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

March 5, 2009

/karla m weyand/

Karla M. Weyand
Reg. No. 40,223

Siemens Healthcare Diagnostics Inc.
511 Benedict Avenue
Tarrytown, NY 10591
Telephone: (914) 524-2741